OncoFirm-PSA
OncoFirm-PSA
Rapid Test for Prostate-Specific Antigen (PSA) Detection
Overview:
OncoFirm-PSA is a fast, reliable, and easy-to-use rapid test for the detection of elevated Prostate-Specific Antigen (PSA) levels—an important biomarker in the early identification and monitoring of prostate cancer. Developed using OncoFirm’s advanced lateral flow assay (LFA) technology, this test provides results within 15 minutes, empowering healthcare professionals to screen patients at the point of care without the need for lab infrastructure.
Key Features:
- PSA Biomarker-Based Detection: Measures total PSA levels in serum, plasma, or whole blood.
- Rapid Results: Delivers clear, easy-to-interpret results in under 15 minutes.
- Clinically Relevant Thresholds: Designed to detect PSA levels above standard clinical cutoffs (e.g., >4 ng/mL).
- Non-Invasive & Convenient: Requires a finger-prick or venous blood sample.
- Point-of-Care Ready: Ideal for use in urology clinics, general practice, and community health screenings.
Clinical Applications:
- Early detection of prostate abnormalities and prostate cancer
- Routine screening in men over 50 or those with family history
- Monitoring PSA levels post-treatment or during active surveillance
- Triage tool to support decisions on further testing (e.g., biopsy, imaging)
Benefits for Medical Providers:
- Enables early risk identification and timely urology referrals
- Reduces wait times and improves patient compliance with PSA screening
- Increases access to prostate health assessments in underserved settings
- Supports population-wide screening initiatives and preventative health programs
Regulatory Status:
OncoFirm-PSA is CE-marked for international markets. Regulatory pathways for FDA approval and global distribution are in progress.
